ReportExtended efalizumab therapy improves chronic plaque psoriasis: Results from a randomized phase III trial
Section snippets
Patients
The study population included adults 18-70 years of age diagnosed with moderate to severe plaque psoriasis for at least 6 months, with clinically stable disease for at least 3 months before screening. Eligible patients had a PASI ≥12, had a body surface area (BSA) involvement ≥10% at screening, and were candidates for systemic therapy. Additional inclusion and exclusion criteria were similar to those in previous efalizumab studies.25, 26 The investigative sites received Institutional Review
Patient characteristics
At baseline, 498 patients were initially randomized, and 183 efalizumab-treated patients who had not achieved PASI-75 at week 12 were re-randomized to receive efalizumab or placebo (Fig 2). With the exception of a younger mean age in the placebo group, there were no significant differences between the treatment groups at baseline (Table I). There were no statistical differences for demographic and baseline characteristics across treatment groups for patients who were randomized into the
Discussion
The results of this large Phase III, randomized, double-blind, placebo-controlled trial demonstrated that extending efalizumab treatment resulted in further improvement in many patients. Both 12- and 24-week treatment periods of efalizumab resulted in significant clinical improvement on multiple measures of treatment efficacy compared to placebo. Significant improvement was noted at the primary endpoint of 12 weeks, with 39% and 27% of patients in the efalizumab 1 mg/kg and 2 mg/kg groups,
References (29)
- et al.
An approach to the treatment of moderate to severe psoriasis with rotational therapy
J Am Acad Dermatol
(1993) - et al.
Injection of pre-psoriatic skin with CD4+ T cells induces psoriasis
Am J Pathol
(1999) - et al.
Effects of administration of a single dose of a humanized monoclonal antibody to CD11a on the immunobiology and clinical activity of psoriasis
J Am Acad Dermatol
(2000) - et al.
Leukocyte membrane adhesion proteins LFA-1, CR3 and p150, 95: a review of functional and regulatory aspects
Res Immunol
(1989) - et al.
Anti-CD11a treatment for psoriasis concurrently increases circulating T-cells and decreases plaque T-cells, consistent with inhibition of cutaneous T-cell trafficking
J Invest Dermatol
(2000) - et al.
Anti-adhesion antibodies. Efalizumab, a humanized anti-CD11a monoclonal antibody
Transpl Immunol
(2002) - et al.
Efficacy and safety of treatment modalities for psoriasis
Cutis
(1998) - et al.
Treatment of psoriasis. Part 2. Systemic therapies
J Am Acad Dermatol
(2001) - et al.
The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey
Arch Dermatol
(2001) - Salonen S-H and the EUROPSO Patient Survey Study Group. The EUROPSO Psoriasis Patient Study: Treatment history and...
Immunocompetent cells in psoriasis: in situ immunophenotyping by monoclonal antibodies
Arch Dermatol Res
Expression of HLA-DR molecules by keratinocytes, and presence of Langerhans cells in the dermal infiltrate of active psoriatic plaques
J Exp Med
Response of psoriasis to a lymphocyte-selective toxin (DAB389-IL2) suggests a primary immune, but not keratinocyte, pathogenic basis
Nat Med
The immunologic basis for the treatment of psoriasis with new biologic agents
J Am Acad Dermatol
Cited by (223)
Representation of older adults in randomized controlled trials on systemic treatment in plaque psoriasis: A systematic review
2020, Journal of the American Academy of DermatologyComparative efficacy and safety of thirteen biologic therapies for patients with moderate or severe psoriasis: A network meta-analysis
2019, Journal of Pharmacological SciencesBiological therapies (immunomodulatory drugs), worsening of psoriasis and rebound effect: new evidence of similitude
2016, HomeopathyCitation Excerpt :Evaluating the course of psoriasis following this forced drug withdrawal, Morell et al.52 conducted a multicenter observational study with 147 patients treated in twelve Spanish hospitals: rebound following withdrawal of efalizumab was observed in 30% (44/142) of patients, and the likelihood of phenomenon was independent of clinical characteristics, duration of treatment or response (responders to treatment or nonresponders), or therapeutic approach used by the dermatologist following suspension (reiterating ‘the common properties of the rebound effect’ initially cited). The authors concluded that “there was a high frequency of rebound following suspension of efalizumab, exceeding the rate reported in pivotal trials.39–45 This is a particularly noteworthy given the large proportion of patients with a good response to treatment and therefore believed to have a better prognosis”.
Pharmacological opportunities to control inflammatory diseases through inhibition of the leukocyte recruitment
2016, Pharmacological ResearchLeukocyte integrins: Role in leukocyte recruitment and as therapeutic targets in inflammatory disease
2015, Pharmacology and Therapeutics
Genentech, Inc. sponsored this clinical research and was the administrative entity for biostatistical review. All of the authors of this report were members of the Efalizumab Study Group.
Drs Feldman, Gordon, Leonardi, and Menter have received grant/research support from, served as consultants for, and served on the speakers bureau for Genentech, Inc. Dr Papp has received grant/research support from and served as consultant to Genentech, Inc., Xoma LLC, and Serono S.A. Dr Walicke was an employee of and is a stock shareholder in Genentech, Inc. Mr Compton is a stock shareholder in and an employee of Genentech, Inc. Dr Gottlieb has received grant/research support from and served as consultant to Genentech, Inc.
- ∗
A complete listing of the principal investigators can be found at the end of this article.